Alice Yen Wen Yam

US Patent:

20110189692, Aug 4, 2011

Filed:

Apr 29, 2009

Appl. No.:

12/990480

Inventors:

David Peretz - El Cerrito CA, US
Xuemei Wang - Castro Valley CA, US
Carol Man Gao - San Ramon CA, US
Alice Yam - Fremont CA, US
Anthony Lau - San Francisco CA, US
Ping Wu - Danville CA, US

International Classification:

G01N 33/68

US Classification:

435 71, 436501

Abstract:

The invention provides methods for detecting the presence of a non-prion pathogenic conformer in a sample by contacting the sample suspected of containing a non-prion pathogenic conformer with a pathogenic conformer-specific binding reagent under conditions that allow the binding of the reagent to the pathogenic conformer, if present; and detecting the presence the pathogenic conformer, if any, in the sample by its binding to the reagent; where the pathogenic conformer-specific binding reagent is typically derived from a prion protein fragment and interacts preferentially with a pathogenic prion protein. Methods for diagnosis of conformational diseases are also provided.

US Patent:

20130109581, May 2, 2013

Filed:

Nov 4, 2010

Appl. No.:

13/508037

Inventors:

David Peretz - Emeryville CA, US
Alice Yam - Emeryville CA, US
Xuemei Wang - Emeryville CA, US
Man Gao - Emeryville CA, US

International Classification:

G01N 33/68

US Classification:

506 9, 435 794, 435 792, 436501, 435 71

Abstract:

The invention provides methods for detecting the presence of an aggregate in a sample by contacting the sample suspected of containing an aggregate with an aggregate-specific binding reagent under conditions that allow the binding of the reagent to the aggregate, if present; and detecting the presence of the aggregate, if any, in the sample by its binding to the reagent; where the aggregate-specific binding reagent typically has a net charge of at least about positive one at the pH at which the sample is contacted with the ASB reagent, is attached to a solid support at a charge density of at least about 60 nmol net charge per square meter, and binds preferentially with aggregates over monomers when attached to the solid support. Methods for detecting the presence of oligomer are also provided. Compositions for use in the methods are provided.

US Patent:

20130273573, Oct 17, 2013

Filed:

Nov 30, 2010

Appl. No.:

13/512858

Inventors:

Sophie Allauzen - Emeryville CA, US
Joseph Fedynyshyn - Emeryville CA, US
David Peretz - Emeryville CA, US
Xuemei Wang - Emeryville CA, US
Alice Yam - Emeryville CA, US

Assignee:

NOVARTIS AG - Basel

International Classification:

G01N 33/543

US Classification:

435 792, 436501, 435 71

Abstract:

The invention provides methods for assessing increased probability of having Alzheimer's disease in a subject under assessment including a step of obtaining a measurement of Aβ40 aggregates in a biological sample from the subject, where the biological sample does not include brain tissue, a fraction of brain tissue, or brain homogenate. In some embodiments, the invention relates to methods of assessing increased probability of early stage Alzheimer's disease. The invention further provides methods of assessing increased probability of not having Alzheimer's disease, methods of monitoring disease progression in a subject with Alzheimer's disease, and methods of assigning disease stage for a subject with Alzheimer's disease, and methods of assessing increased probability of MCI progressing to Alzheimer's disease.

US Patent:

20100196934, Aug 5, 2010

Filed:

Apr 3, 2008

Appl. No.:

12/450636

Inventors:

David Peretz - El Cerrito CA, US
Alice Yam - Fremont CA, US

International Classification:

G01N 33/53

US Classification:

435 792

Abstract:

The invention relates to an assay method for detecting the presence of PrPusing at least one sequence-specific protease for a substantially complete digestion of the proteins in a sample, leaving the octarepeat region in both PrPand PrPintact, leaving the protease-resistant core of PrPintact and remain connected to the octarepeat region, region, while digesting away at least part of the amino acid sequences in PrPcorresponding to the protease-resistant core in PrP. The method further comprises a step of inhibiting further digestion by the protease, a step of denaturation, and a step of detecting the presence of PrPusing at least two binding partners, a first binding partner and a second binding partner, wherein the first binding partner specifically binds an epitope in the amino-proximal region, and the second binding partner specifically binds an epitope within a region of the protease-resistant core of PrPthat has been cleaved away in PrP. The invention also relates to a kit comprising reagents that can be used in the assay method.

US Patent:

20220362394, Nov 17, 2022

Filed:

May 1, 2020

Appl. No.:

17/608100

Inventors:

- South San Francisco CA, US
Ryan STAFFORD - Emeryville CA, US
Alice YAM - Tiburon CA, US
Xiaofan LI - Fremont CA, US
Abigail YU - San Jose CA, US
Amandeep GAKHAL - San Mateo CA, US
Stephanie ARMSTRONG - South San Francisco CA, US

Assignee:

SUTRO BIOPHARMA, INC. - South San Francisco CA

International Classification:

A61K 47/68
C07K 16/28
A61P 35/00

Abstract:

The present disclosure relates to antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods.

US Patent:

20220323599, Oct 13, 2022

Filed:

May 1, 2020

Appl. No.:

17/608097

Inventors:

- Summit NJ, US
Ryan STAFFORD - Emeryville CA, US
Alice YAM - Tiburon CA, US
Xiaofan LI - Fremont CA, US
Abigail YU - San Jose CA, US
Amandeep GAKHAL - San Mateo CA, US

Assignee:

CELGENE CORPORATION - Summit NJ

International Classification:

A61K 47/68
C07K 16/28
A61P 35/02

Abstract:

The present disclosure relates to antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods.

US Patent:

20210403558, Dec 30, 2021

Filed:

May 6, 2021

Appl. No.:

17/313511

Inventors:

- South San Francisco CA, US
Alice YAM - Tiburon CA, US
John LEE - San Francisco CA, US
Junhao YANG - Foster City CA, US
Aaron SATO - Burlingame CA, US

International Classification:

C07K 16/28

Abstract:

Provided herein are antibodies that selectively bind to Tim-3 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

US Patent:

20210340207, Nov 4, 2021

Filed:

Apr 20, 2021

Appl. No.:

17/234844

Inventors:

- Rahway NJ, US
Edward Bowman - Redwood City CA, US
Xiaofan Li - Belmont CA, US
Songnian Lin - Holmdel NJ, US
Willy Solis - San Mateo CA, US
Ryan Stafford - Foster City CA, US
Aarron Willingham - Mountain View CA, US
Alice Yam - Belmont CA, US
Junhao Yang - Milpitas CA, US
Gang Yin - South San Francisco CA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07K 14/55
A61P 35/00
A61K 47/60
C07K 16/28
A61K 47/54

Abstract:

Interleukin-2 (IL-2) conjugates comprising at least one or more amino acid substitutions that bias binding to the IL-2 receptor βγdimer over binding the IL-2 receptor αβγtrimer and a non-natural amino acid at or near the N-terminus conjugated to a water-soluble polymer are described. The IL-2 conjugates are useful for treatment and prevention of cell proliferation and cancer in a patient.